Denosumab: a promise for treatment of postmenopausal osteoporosis

Abstract

Denosumab is the first monoclonal antibody agency for the treatment of postmenopausal osteoporosis recently. Denosumab binds to receptor activator of nuclear factor-κB ligand (RANKL) and inhibits bone resorption by means of reducing the formation,function and survival of osteoclasts. Clinical trials have shown that denosumab increased bone mineral density ( BMD) and reduced fracture risk superior to placebo and alendronate in postmenopausal osteoporosis women. The profile of adverse events in treatment is similar to placebo and alendronate. The pharmacoeconomic studies of denosumab have shown that denosumab may be an alternative to oral osteoporosis treatment because of its better cost effective ratio. There is a promise for denosumab to be a new option in treatment of postmenopausal osteoporosis. Key words: Denosumab; Osteoporosis; Bone mineral density; Menostasia; Treatment